Gregory Madison

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Kidney Care Partners provides healthcare services. It specializes in patient survival, hospitalization and patient experience with care. The company was founded in May 2003 and is headquartered in Washington, DC.

Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA.

Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.

The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD.

Phosphate Therapeutics Ltd. provides research and experimental development on biotechnology. It engages in development of drug named PT20 to cure high phosphate levels in blood. The company was founded in 2011 and is headquartered in Gateshead Quays, the United Kingdom.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.